874 related articles for article (PubMed ID: 25818419)
1. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z
Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419
[TBL] [Abstract][Full Text] [Related]
2. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer.
Zhou J; Zhao WY; Ma X; Ju RJ; Li XY; Li N; Sun MG; Shi JF; Zhang CX; Lu WL
Biomaterials; 2013 May; 34(14):3626-38. PubMed ID: 23422592
[TBL] [Abstract][Full Text] [Related]
3. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
[TBL] [Abstract][Full Text] [Related]
4. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells.
Wang XX; Li YB; Yao HJ; Ju RJ; Zhang Y; Li RJ; Yu Y; Zhang L; Lu WL
Biomaterials; 2011 Aug; 32(24):5673-87. PubMed ID: 21550109
[TBL] [Abstract][Full Text] [Related]
5. Overcoming drug-resistant lung cancer by paclitaxel-loaded hyaluronic acid-coated liposomes targeted to mitochondria.
Tian Y; Zhang H; Qin Y; Li D; Liu Y; Wang H; Gan L
Drug Dev Ind Pharm; 2018 Dec; 44(12):2071-2082. PubMed ID: 30112929
[TBL] [Abstract][Full Text] [Related]
6. Antitumor Effect of Hyperoside Loaded in Charge Reversed and Mitochondria-Targeted Liposomes.
Feng Y; Qin G; Chang S; Jing Z; Zhang Y; Wang Y
Int J Nanomedicine; 2021; 16():3073-3089. PubMed ID: 33953556
[TBL] [Abstract][Full Text] [Related]
7. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
Li N; Zhang CX; Wang XX; Zhang L; Ma X; Zhou J; Ju RJ; Li XY; Zhao WY; Lu WL
Biomaterials; 2013 Apr; 34(13):3366-80. PubMed ID: 23410681
[TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C
Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537
[TBL] [Abstract][Full Text] [Related]
9. Anti-Cancer Efficacy of Paclitaxel Loaded in pH Triggered Liposomes.
Jiang L; He B; Pan D; Luo K; Yi Q; Gu Z
J Biomed Nanotechnol; 2016 Jan; 12(1):79-90. PubMed ID: 27301174
[TBL] [Abstract][Full Text] [Related]
10. DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.
Chang Q; Geng R; Wang S; Qu D; Kong X
Drug Deliv; 2016 Nov; 23(9):3629-3638. PubMed ID: 27749106
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
Bai F; Wang C; Lu Q; Zhao M; Ban FQ; Yu DH; Guan YY; Luan X; Liu YR; Chen HZ; Fang C
Biomaterials; 2013 Aug; 34(26):6163-74. PubMed ID: 23706689
[TBL] [Abstract][Full Text] [Related]
12. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
[TBL] [Abstract][Full Text] [Related]
13. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
Shi C; Cao H; He W; Gao F; Liu Y; Yin L
Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes.
Meng S; Su B; Li W; Ding Y; Tang L; Zhou W; Song Y; Li H; Zhou C
Nanotechnology; 2010 Oct; 21(41):415103. PubMed ID: 20852356
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma.
Yu Y; Wang ZH; Zhang L; Yao HJ; Zhang Y; Li RJ; Ju RJ; Wang XX; Zhou J; Li N; Lu WL
Biomaterials; 2012 Feb; 33(6):1808-20. PubMed ID: 22136714
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy.
Riaz MK; Zhang X; Wong KH; Chen H; Liu Q; Chen X; Zhang G; Lu A; Yang Z
Int J Nanomedicine; 2019; 14():2879-2902. PubMed ID: 31118613
[No Abstract] [Full Text] [Related]
17. Aminoglucose-functionalized, redox-responsive polymer nanomicelles for overcoming chemoresistance in lung cancer cells.
Zhou Y; Wen H; Gu L; Fu J; Guo J; Du L; Zhou X; Yu X; Huang Y; Wang H
J Nanobiotechnology; 2017 Nov; 15(1):87. PubMed ID: 29179722
[TBL] [Abstract][Full Text] [Related]
18. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer.
Zhang Y; Li RJ; Ying X; Tian W; Yao HJ; Men Y; Yu Y; Zhang L; Ju RJ; Wang XX; Zhou J; Chen JX; Li N; Lu WL
Mol Pharm; 2011 Feb; 8(1):162-75. PubMed ID: 21062083
[TBL] [Abstract][Full Text] [Related]
19. Improved Antitumor Activity of Novel Redox-Responsive Paclitaxel-Encapsulated Liposomes Based on Disulfide Phosphatidylcholine.
Du Y; Wang Z; Wang T; He W; Zhou W; Li M; Yao C; Li X
Mol Pharm; 2020 Jan; 17(1):262-273. PubMed ID: 31747284
[TBL] [Abstract][Full Text] [Related]
20. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery.
Jiang T; Zhang Z; Zhang Y; Lv H; Zhou J; Li C; Hou L; Zhang Q
Biomaterials; 2012 Dec; 33(36):9246-58. PubMed ID: 23031530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
